Tegoprazan and the risk of end-stage kidney disease progression: a nationwide Korean study
Abstract
Background
Tegoprazan, a potassium-competitive acid blocker used in South Korea since 2018, was examined in this study for its potential association with death or progression to end-stage kidney disease (ESKD) among patients with stage 3 or 4 chronic kidney disease (CKD) prescribed tegoprazan for more than 90 days.
Methods
This real-world, retrospective study used national claims data from South Korea recorded between 2013 and 2022. Three independent pairwise analyses were conducted after 1:1 propensity score matching (PSM), comparing the risks of death or ESKD progression between CKD-tegoprazan and CKD-histamine 2 receptor agonists (H2RAs), CKD-tegoprazan and CKD-proton pump inhibitors (PPIs), and CKD-PPIs and CKD-H2RAs. Each outcome was compared using a Cox proportional hazards model, and results were combined in a network meta-analysis.
Results
After PSM, 674, 902, and 4,583 pairs of patients' data were available for each analysis, respectively. Nearly 50% of patients were aged 75 or older. More than 85%, 45%, and 28% of the patients had hypertension, diabetes, and ischemic heart disease, respectively, and approximately 70% were prescribed an antithrombotic agent. The risk of death or ESKD was not increased in the CKD-tegoprazan cohort compared to CKD-H2RA (hazard ratio, 0.91 [95% confidence interval, 0.66-1.26]; p = 0.57) or CKD-PPIs (hazard ratio, 0.87 [95% confidence interval, 0.66-1.15]; p = 0.32). Network meta-analysis yielded the same trends.
Conclusion
In patients…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 4,583 participants or records.
Read the paper
Related studies
- Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.